Study of SHR-A1921 plus adebrelimab for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (SHR-A1921 and adebrelimab) for people with advanced non-small cell lung cancer whose cancer has grown after standard first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer that cannot be removed by surgery.
- Your tumor does not have certain gene changes (EGFR, ALK, or ROS1) if you have non-squamous cell cancer.
- Your cancer has progressed after previous treatment with an immunotherapy (PD-1/L1 antibody) or platinum chemotherapy.
- You have at least one measurable tumor (by scan).
- You are in generally good health (able to care for yourself, ECOG 0-1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, SHR-A1921 and SHR-A2009, for people with advanced non-small cell lung cancer that has progressed after prior treatment with an antibody-drug conjugate. The goal is to see if these drugs can shrink tumors and help patients live longer.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (SHR-A1811 and Adebelimumab) given before surgery for people with a specific type of lung cancer that has changes in the HER2 gene. The goal is to see if this treatment can shrink the tumor and make surgery more effective.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.